熱門資訊> 正文
Zentalis Pharmaceuticals任命Julie Eastland为首席执行官
2024-11-13 21:46
- Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that Julie Eastland has been appointed Chief Executive Officer, President and Director, succeeding Kimberly Blackwell, who will remain as a strategic advisor to the Board of Directors.
- Eastland served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck in early 2024.
- In addition to Eastland’s appointment, Ingmar Bruns, has been appointed Chief Medical Officer.
- The company also announced that Scott Myers has been appointed as Chairperson of the Zentalis Board of Directors.
- Source: Press Release
More on Zentalis Pharmaceuticals
- Zentalis stock rises after FDA lifts partial clinical hold on azenosertib studies
- Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals
- Historical earnings data for Zentalis Pharmaceuticals
- Financial information for Zentalis Pharmaceuticals
推薦文章
華盛早報 | 對美聯儲「開刀」！特朗普火速罷免理事庫克；拼多多高管稱亮眼淨利潤「不可持續」
港股「DeepSeek」時刻或已來臨！補漲行情即將啟動？
鮑威爾鴿聲助力，美小盤股強勢反彈！美銀、瑞銀加入看多陣營
8月26日外盤頭條：美國將銅和鉀鹽列入關鍵礦物清單 馬斯克起訴蘋果和OpenAI 英特爾警告國際業務風險
一圖看懂 | 拼多多盤前飆升11%！Q2營收、淨利潤大超市場預期
新股暗盤 | 雙登股份大漲244%！中籤一手賺超1.77萬港元
今年的傑克遜霍爾會議氣氛不比往年輕松 折射美聯儲未來道路艱難
「AI信仰」迎大考！美股新高之路的「重磅關卡」：英偉達(NVDA.US)本周能否交出完美財報？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
